Ask AI
Pancreatic Cancer Progress

CE / CME

Pancreatic Cancer Progress: Enhancing Knowledge and Optimizing Innovations in Patient Care

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: September 03, 2025

Expiration: March 02, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 62-year-old man with newly diagnosed metastatic pancreatic ductal adenocarcinoma (mPDAC) presents with an ECOG performance status of 1. He has no significant comorbidities and normal hepatic and renal function. Molecular profiling is pending. He is eager to pursue aggressive treatment.

Based on current evidence and guidelines, which of the following is the most appropriate first-line therapy?

2.

A 58-year-old woman with metastatic mPDAC was initially treated with NALIRIFOX and achieved a partial response. After 6 months, her disease progresses. She maintains an ECOG performance status of 1 and has no significant organ dysfunction. Molecular testing reveals no actionable mutations.

Based on current evidence and guidelines, which of the following is the most appropriate next-line therapy?

3.

Which of the following strategies is most appropriate for mitigating chemotherapy-induced adverse events in patients receiving systemic therapy for mPDAC?